(Q37528441)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

main subject

angiogenesis inhibitor

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2

Patrick Y Wen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

David P Samuel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

973-983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

New developments in targeted molecular therapies for glioblastoma.

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Tumoral angiogenesis: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic chemotherapy: an antiangiogenic scheduling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic dosing of chemotherapy: applications in pediatric oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Anti-angiogenic therapy in pediatric neuro-oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Chronic oral VP-16 for recurrent medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Treatment with oral etoposide for childhood recurrent ependymomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Recurrent brainstem gliomas treated with oral VP-16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Antiangiogenesis therapy. Current and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

COX-2 inhibitors. A new class of antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Combined anti-proliferative and anti-angiogenic strategies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903025752

10.1517/13543780903025752

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19548852%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference